C4 Therapeutics, Inc. (CCCC)
Nasdaq: CCCC · Biological Products, (No Diagnostic Substances) · Watertown, MA · filing with the SEC since 2016
Who owns C4 Therapeutics, Inc.
As filed with the SECHolders of 5% or more
7
Lynx1 Capital Management LP holds 9.99% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
15
report now, of 27 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 7 named at left.
Holders of 5% or moreshare of the class, as filed
Lynx1 Capital Management LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share · 7.3% in Feb 17, 2026
Soleus Capital Master Fund, L.P.
SCHEDULE 13G/A · filed Feb 12, 2026 · Common Stock, par value $0.0001 per share
RA Capital Management, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share · 9.9% in Oct 24, 2025
Sirenia Capital Management LP
SCHEDULE 13G · filed May 15, 2026 · Common Stock, par value $0.0001 per share
Squadron Master Fund LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share · 5% in May 19, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Jul 27, 2026 · Common Stock · 2.5% in Jul 16, 2025
BCLS II Equity Opportunities, LP
SCHEDULE 13G · filed Oct 24, 2025 · Common Stock, par value $0.0001 per share
Morgan Stanley
SCHEDULE 13G/A · filed Aug 12, 2026 · Common Stock · reported falling below 5%, from 9.3% in Feb 11, 2026
Wasatch Advisors LP
SCHEDULE 13G/A · filed Apr 22, 2026 · COM STK · reported falling below 5%, from 6.8% in Nov 13, 2025
OrbiMed Capital LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5% in Nov 14, 2025
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 9.9% in Oct 20, 2025
What CCCC reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
1sales
0purchases
0sales on a scheduled plan
1people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 2, 2025 to Oct 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window1 of 27 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Reyno Leonard | Chief Medical Officer | 1 | $0 | 0 | 0 | $0 |